Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of JTT-251 in Healthy and Type 2 Diabetic Subjects
NCT02106585Phase 1Completed
- Sponsor
- Akros Pharma Inc.
- Start
- Mar 2014
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of JTT-251 in type 2 diabetes mellitus (T2DM) (9 arms), sponsored by Akros Pharma Inc. Primary endpoints: Number of subjects with adverse events at 1 week, Vital signs and 12 lead ECGs at 1 week and 4 more. Started Mar 2014; status: completed.
02
Drugs
JTT-251
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02106585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02106585.